dehydroepiandrosterone

(redirected from Prasterone)
Also found in: Medical, Encyclopedia.

de·hy·dro·ep·i·an·dros·te·rone

 (dē′hī-drō-ĕp′ē-ăn-drŏs′tə-rōn′)
n.
DHEA.
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.

dehydroepiandrosterone

(diːˌhaɪdrəʊˌɛpɪænˈdrɒstəˌrəʊn)
n
(Biochemistry) the most abundant steroid in the human body, that is involved in the manufacture of testosterone, oestrogen, progesterone, and corticosterone
Collins English Dictionary – Complete and Unabridged, 12th Edition 2014 © HarperCollins Publishers 1991, 1994, 1998, 2000, 2003, 2006, 2007, 2009, 2011, 2014
Translations

dehydroepiandrosterone (DHEA)

n dehidroepiandrosterona (DHEA)
English-Spanish/Spanish-English Medical Dictionary Copyright © 2006 by The McGraw-Hill Companies, Inc. All rights reserved.
Mentioned in ?
References in periodicals archive ?
Currently, 2 drugs such as BP101 and Prasterone 6.5 mg vaginal insert are under phase 3 clinical trial are being investigated for its safety and efficacy for the treatment of HSDD.
* Neither intravaginal dehydroepiandrosterone (DHEA; prasterone) nor the oral selective estrogen receptor modulator ospemifene has been studied in breast cancer survivors.
Some FDA-approved treatment options for dyspareunia include ospemifene, prasterone. estradiol soft gels, and carbon dioxide laser therapy (Thomas et al., 2018).
NEITHER AGE NOR previous hormone therapy had statistically significant associations with the effect of intravaginal prasterone on dyspareunia severity, according to a new subgroup analysis of clinical trial data.
Amag Pharmaceutical and Endoceutics announced an oral presentation regarding the effect of time since menopause, age, and previous hormone therapy on treatment efficacy of intravaginal 6.5 mg prasterone at the Annual Meeting of The North American Menopause Society, or NAMS.
Theramex has entered into a definitive commercial agreement with Endoceutics for Intrarosa (Prasterone), the private pharmaceutical company disclosed on Thursday.
Quebec, Canada, January 15, 2018 --(PR.com)-- The European Commission has adopted the following on 8 January 2018: Adoption of Commission Implementing Decision granting marketing authorisation under Regulation (EC) No 726/2004 of the European Parliament and of the Council for "Intrarosa - Prasterone," a medicinal product for human use.
acolbifene hydrochloride + prasterone + GnRH agonist - Drug Profile 81
Intrarosa is the first FDA product containing the active ingredient prasterone, which is also known as dehydroepiandrosterone (DHEA).
Advances in SLE treatment currently encompass the use of immunomodulators including prasterone (synthetic dehydroeipandrosterone), vitamin D, hydroxychloroquine, and belimumab.
Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone).